Physician profile
Michael J Levitt
NPI 1891979381
$150,498.40
in general payments reported to CMS, 2019-2025
66 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $17K · 2021: $14K · 2022: $24K · 2023: $3,138 · 2024: $15K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $5,550 · Food and Beverage: $4,592 · Travel and Lodging: $2,467 · Education: $84.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,765.00 |
| Consulting Fee | $5,550.00 |
| Food and Beverage | $4,591.54 |
| Travel and Lodging | $2,466.87 |
| Education | $84.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44,235.64 | 2020-2025 | Ojjaara |
| Amgen INC. | $27,840.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19,755.59 | 2019-2023 | Ninlaro |
| Incyte Corporation | $14,908.52 | 2020-2025 | Monjuvi, Monjuvi, Pemazyre |
| Pharmacosmos Therapeutics INC. | $14,335.24 | 2024-2025 | Cosela, Monoferric |
| Taiho Oncology, INC. | $13,444.30 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,848.76 | 2019-2025 | Calquence, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $3,392.21 | 2019-2025 | Opdivo, Opdualag |
| Aveo Pharmaceuticals, INC. | $1,830.62 | 2021-2023 | Fotivda |
| Exelixis INC. | $722.12 | 2020-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $714.63 | 2019-2025 | |
| Gilead Sciences, INC. | $397.91 | 2019-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $375.76 | 2019-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $333.96 | 2019-2024 | Keytruda, Reblozyl, Welireg |
| Eisai INC. | $330.22 | 2019-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.71 | 2019-2025 | |
| Seagen INC. | $264.96 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Genentech USA, INC. | $253.00 | 2019-2025 | Itovebi, Lunsumio, Tecentriq |
| Myriad Genetic Laboratories, INC. | $209.20 | 2023 | Myrisk |
| Janssen Biotech, INC. | $208.33 | 2019-2024 | Tecvayli, Talvey, Erleada |
| Janssen Pharmaceuticals, INC | $182.71 | 2019-2023 | Xarelto |
| Celgene Corporation | $178.25 | 2019-2023 | Reblozyl |
| Lilly USA, LLC | $176.80 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $157.29 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $151.65 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Kite Pharma, INC. | $151.45 | 2021-2025 | Yescarta |
| Stemline Therapeutics INC. | $144.35 | 2024-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $141.65 | 2020-2022 | |
| Daiichi Sankyo INC. | $138.39 | 2023-2025 | Enhertu |
| Astellas Pharma US INC | $121.73 | 2019-2022 | |
| Mirati Therapeutics, INC. | $112.17 | 2023-2024 | Krazati |
| Genzyme Corporation | $99.80 | 2019-2023 | |
| Puma Biotechnology, INC. | $98.34 | 2019-2023 | Nerlynx |
| Pfizer INC. | $91.97 | 2019-2024 | |
| Emd Serono, INC. | $73.82 | 2021-2024 | Bavencio |
| Beigene USA, INC. | $62.44 | 2021-2025 | Brukinsa |
| Springworks Therapeutics, INC. | $56.97 | 2024-2025 | Ogsiveo |
| Regeneron Healthcare Solutions, INC. | $47.34 | 2019-2024 | Libtayo |
| Apellis Pharmaceuticals, INC. | $37.03 | 2023 | Empaveli |
| Foundation Medicine, INC. | $35.49 | 2021-2022 | |
| Geron Corporation | $34.21 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $33.81 | 2023-2024 | Provenge |
| Agios Pharmaceuticals, INC. | $33.18 | 2022-2023 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.24 | 2021-2023 | Gilotrif |
| Eusa Pharma (US) LLC | $29.47 | 2019-2021 | |
| Myovant Sciences INC. | $28.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.58 | 2019 | |
| Servier Pharmaceuticals LLC | $26.89 | 2024 | |
| Acceleron Pharma, INC. | $26.06 | 2020-2021 | |
| Beone Medicines USA, INC. | $23.37 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $23.16 | 2020 | |
| Array Biopharma INC | $18.72 | 2025 | Lorbrena, Mektovi, Braftovi |
| Sirtex Medical INC | $18.19 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $16.60 | 2023 | Qinlock |
| Genmab U.S., INC. | $16.33 | 2023 | Epkinly |
| Adc Therapeutics America, INC. | $15.26 | 2024 | |
| Mylan Institutional INC. | $14.88 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.81 | 2022 | |
| Tesaro, INC. | $14.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.66 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.18 | 2019 | |
| Epizyme, INC. | $14.10 | 2021 | |
| Emmaus Medical, INC. | $13.89 | 2021 | |
| Dova Pharmaceuticals | $13.08 | 2021 | |
| Kyowa Kirin, INC. | $13.07 | 2023 | Poteligeo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.